Kairos Pharma, LTD. (KAPA) Form 10-Q — May 13, 2026
Kairos Pharma, Ltd. reported a net loss of $1,654 for the three months ended March 31, 2026, compared to a net loss of $1,262 for the same period in 2025. The company's cash and cash equivalents decreased from $4,491 as of December 31, 2025 to $3,675 as of March 31, 2026. The company raised gross proceeds of $385 through the sale of 589,845 shares of its common stock under an At the Market (ATM) offering.
Key figures
- Eps Beat
- 0
- Revenue
- 0
- Total Debt
- 0
- Debt Amount
- 0
- Revenue Yoy
- 0
- Total Assets
- 0
- Cash Position
- 3675
- Deal Value Usd
- 0
- Interest Rate
- 0
- Gross Proceeds
- 385
- Offering Price
- 0
- Shares Offered
- 589845
- Shares Outstanding
- 21411198
- Net cash provided by financing activities
- 220
Price after filing
1 day: +6.1%7 days: +10.6%30 days: -1.3%
Close on the filing date to close N calendar days later (from $0.46). Historical, not a forecast.
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.